Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development

The United States radiation medical countermeasures (MCM) programme for radiological and nuclear incidents has been focusing on developing mitigators for the acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE), and biodosimetry technologies to provide radiation dos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of radiological protection 2014-06, Vol.34 (2), p.R25-R52
Hauptverfasser:	Yoo, Stephen S, Jorgensen, Timothy J, Kennedy, Ann R, Boice Jr, John D, Shapiro, Alla, Hu, Tom C-C, Moyer, Brian R, Grace, Marcy B, Kelloff, Gary J, Fenech, Michael, Prasanna, Pataje G S, Coleman, C Norman
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Biological effects of radiation Drug Design Fundamental and applied biological sciences. Psychology Humans Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasms, Radiation-Induced - diagnosis Neoplasms, Radiation-Induced - prevention & control Radiation Dosage radiation mitigator Radiation Protection - methods radiation risk radiation-induced cancer Radiation-Protective Agents - chemical synthesis Radiation-Protective Agents - therapeutic use Radioactive Hazard Release Radiometry - methods Radioprotection radioprotector Risk Assessment - methods Tissues, organs and organisms biophysics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!